Promiscuous survivin peptide induces robust CD4 + T-cell responses in the majority of vaccinated cancer patients

International Journal of Cancer

Volumn 131, Issue 1, 2012, Pages 140-149

  Widenmeyer, Melanie ^a   Griesemann, Heinrich ^a   Stevanović, Stefan ^a   Feyerabend, Susan ^a   Klein, Reinhild ^a   Attig, Sebastian ^a,e   Hennenlotter, Jörg ^a   Wernet, Dorothee ^b   Kuprash, Dmitri V ^c   Sazykin, Alexei Y ^d   Pascolo, Steve ^a,f   Stenzl, Arnulf ^a   Gouttefangeas, Cécile ^a   Rammensee, Hans Georg ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

MHC epitope; survivin; T helper cell; tumor vaccination

Indexed keywords

EPITOPE; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; SURVIVIN;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL EVALUATION; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VIVO STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-DRB1 CHAINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84860224443     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26365     Document Type: Article

References (50)

1. Li FZ, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC,. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
2. Ambrosini G, Adida C, Altieri DC,. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
3. Grossman D, Mcniff JM, Li F, Altieri DC,. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113: 1076-81.
4. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T,. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92: 271-8.
5. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P,. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571-6.
6. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-5.
7. Islam A, Kageyama H, Takada N, Kawamato T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A,. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19: 617-23.
8. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC,. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341: 452-3.
9. Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS,. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett 2001; 76: 169-73.
10. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, Shroyer KR,. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001; 32: 119-25.
11. Fukuda S, Pelus LM,. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087-98.
12. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP,. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60: 4845-9.
13. Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH,. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer 2004; 108: 937-41.
14. Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005; 11: 1474-82.
15. Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, Belli F, Mezzanzanica D, Costa A, Andreola S, Leo E, Parmiani G, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003; 63: 4507-15.
16. Reuschenbach M, von Knebel DM, Wentzensen N,. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009; 58: 1535-44.
17. Piesche M, Hildebrandt Y, Zettl F, Chapuy B, Schmitz M, Wulf G, Trumper L, Schroers R,. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum Immunol 2007; 68: 572-6.
18. Wang XF, Kerzerho J, Adotevi O, Nuyttens H, Badoual C, Munier G, Oudard S, Tu S, Tartour E, Maillere B,. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol 2008; 181: 431-9.
19. Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M, Ba Y, Becker JC, Reisfeld RA,. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005; 65: 553-61.
20. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A,. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170: 5391-7.
21. Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos AK, Quest AF, Kiessling R,. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother 2010; 59: 81-92.
22. Fuessel S, Meye A, Schmitz M, Zastrow S, Linne C, Richter K, Lobel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP,. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006; 66: 811-21.
23. Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19.
24. Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LO, Rath JC, Bock M, Brocker EB, Straten PT, Kampgen E, Becker JC,. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23: 884-9.
25. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC,. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55: 1294-8.
26. Hadrup SR, Gehl J, Sorensen RB, Geertsen PF, Straten PT, Andersen MH,. Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther 2006; 5: 480-2.
27. Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Kuczyk M, Rammensee HG, Stenzl A,. Novel multi-peptide vaccination In Hla-A2+hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009; 69: 917-27.
28. Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, Jarrossay D, Wagner H, Jung G, Rammensee HG, Hoerr I, Pascolo S,. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 2005; 35: 1557-66.
29. Shebzukhov YV, Lavrik IN, Karbach J, Khlgatian SV, Koroleva EP, Belousov PV, Kashkin KN, Knuth A, Jager E, Chi NW, Kuprash DV, Nedospasov SA,. Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. Cancer Immunol Immunother 2008; 57: 871-81.
30. Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus J, Haas I, Mackensen A, et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008; 57: 289-302.
31. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, Gouttefangeas C,. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009; 69: 8412-9.
32. Turvy DN, Blum JS,. Detection of biotinylated cell surface receptors and MHC molecules in a capture ELISA: a rapid assay to measure endocytosis. J Immunol Methods 1998; 212: 9-18.
33. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004; 10: 929-37.
34. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ,. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-3.
35. Sun JC, Williams MA, Bevan MJ,. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004; 5: 927-33.
36. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP,. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421: 852-6.
37. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H,. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999; 96: 8633-8.
38. Qin ZH, Blankenstein T,. CD4(+) T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677-86.
39. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13: 507-18.
40. Perez-Diez A, Joncker NT, Choi K, Chan WFN, Anderson CC, Lantz O, Matzinger P,. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-54.
41. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ,. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187: 693-702.
42. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G,. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-88.
43. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007; 104: 12837-42.
44. Slingluff CL, Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008; 26: 4973-80.
45. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C,. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-703.
46. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, Hill BJ, Roederer M, Douek DC, Koup RA,. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006; 203: 2865-77.
47. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF,. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004; 20: 107-18.
48. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, Juenger S, Vlodavsky I, Khazaie K, Jaeger D, Reissfelder C, Antolovic D, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119: 3311-21.
49. van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den HM, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R,. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 2007; 104: 12087-92.
50. Francois V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, Van Der BP,. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 2009; 69: 4335-45.